Biogen [clinicaltrials_resource:b34193a9204d2f50d15aedf8b222dbad]
Michael Panzara, MD, MPH [clinicaltrials_resource:13f985fef15b12b7afce0796be134c7d]Abraham Kroon, MD, PhD [clinicaltrials_resource:1526800ff7e961797416facd992a3b32]Biogen Idec [clinicaltrials_resource:1e5f125262de7643fe1c773ce546c417]Pamela Foulds, MD [clinicaltrials_resource:209e4d9fb2e572fab002957c91bf4f21]Evan Beckman, MD [clinicaltrials_resource:23d41bf63e54ecdc0ec2d133b916560d]Katrina Nguyen [clinicaltrials_resource:2796f9bac7cd376a4faaafaa7dc6f5ea]Biogen Idec Medical Monitor, MD [clinicaltrials_resource:2cf7b1eed5be0bad25699c371dcbdd2a]Medical Director [clinicaltrials_resource:2e2df1f58a462556e42a5f4e93d61590]Biogen-Idec Medic, MD [clinicaltrials_resource:3994459ab2efc683fd70cf2d9e04e78d]Antonio J. Grillo-Lopez, M.D. [clinicaltrials_resource:4674e63f51cf463a57e92884ce40535d]Medical Director [clinicaltrials_resource:4a823d2988df8316f8e8061b6441a633]Medical Director [clinicaltrials_resource:5071f0d7da74ee7b13569d997b9d0cf2]Barry Ticho, MD [clinicaltrials_resource:5b1e13fa1f2bab3bd6427aea86fab393]Medical Director [clinicaltrials_resource:5d991f2a3092bc6a235ea17490886d23]Chris Storgard, MD [clinicaltrials_resource:5e868f25ecd092292c5a656f1a26966a]Biogen Idec, MD [clinicaltrials_resource:6717a759e001d2ba74ecc3c6c8784392]Medical Director [clinicaltrials_resource:6f66ace1a525faf10c89b089b36463b4]Medical Director [clinicaltrials_resource:76376ea3b649267a330c488870898361]Biogen-Idec Investigator [clinicaltrials_resource:8609b17740446c5068cd52274f8ba8a3]Medical Director [clinicaltrials_resource:8a691d219dceada090b080eff9a091fc]Biogen-Idec Investigator [clinicaltrials_resource:8b01371fe80f33ec1f35cbcf0a69b9a0]Thorsten Eickenhorst, MD [clinicaltrials_resource:9992d6ab04aa2925913fcd43ca6d1f06]Biogen-Idec Study Director [clinicaltrials_resource:9e7d3249f0807614454b2f623dfb7914]Michael Panzara, MD MPH [clinicaltrials_resource:aab738a51a1e9d08fe0131bd33f3ee2c]Katrina Nguyen [clinicaltrials_resource:b1ebcb009df8540bb5a4a95e5f5408fa]Biogen-Idec Investigator, MD [clinicaltrials_resource:e14f8f1837aaec278c9dfb0790fa7611]Wayne Saville [clinicaltrials_resource:f6faca325fb9a59d99e173928301360b]
affiliation [clinicaltrials_vocabulary:affiliation]
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis [clinicaltrials:NCT00027300]Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis [clinicaltrials:NCT00030966]Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis [clinicaltrials:NCT00097760]clinicaltrials:NCT00298272clinicaltrials:NCT00306592clinicaltrials:NCT00390221Evaluation of Natalizumab for thE Relief of MS Associated FatiGue [clinicaltrials:NCT00464074]Pregnancy Exposure Registry for Tysabri® [clinicaltrials:NCT00472992]clinicaltrials:NCT00516893Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) [clinicaltrials:NCT00559702]ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay. [clinicaltrials:NCT00618267]Phase I/IIa Study of FIXFc in Hemophilia B Patients [clinicaltrials:NCT00716716]A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State [clinicaltrials:NCT00744679]clinicaltrials:NCT00746941clinicaltrials:NCT00870740clinicaltrials:NCT00871780clinicaltrials:NCT01027364clinicaltrials:NCT01051349clinicaltrials:NCT01058005clinicaltrials:NCT01064401A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple Sclerosis [clinicaltrials:NCT01065090]clinicaltrials:NCT01070823clinicaltrials:NCT01071083clinicaltrials:NCT01181128clinicaltrials:NCT01211665Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients [clinicaltrials:NCT01211678]A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers [clinicaltrials:NCT01215084]Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials. [clinicaltrials:NCT01235221]clinicaltrials:NCT01440946clinicaltrials:NCT01458106clinicaltrials:NCT01797965Daclizumab Japanese PK Study [clinicaltrials:NCT01929746]clinicaltrials:NCT02234310clinicaltrials:NCT02234323clinicaltrials:NCT02386553Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes [clinicaltrials:NCT02392156]clinicaltrials:NCT02462759clinicaltrials:NCT02502149
collaborator [clinicaltrials_vocabulary:collaborator]
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis [clinicaltrials:NCT00027300]Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis [clinicaltrials:NCT00030966]Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas [clinicaltrials:NCT00031083]Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL) [clinicaltrials:NCT00046488]Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma [clinicaltrials:NCT00048555]Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma [clinicaltrials:NCT00057343]Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma [clinicaltrials:NCT00090038]Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis [clinicaltrials:NCT00097760]Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) [clinicaltrials:NCT00099489]Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma [clinicaltrials:NCT00102024]Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) [clinicaltrials:NCT00103558]Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors [clinicaltrials:NCT00105170]Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases [clinicaltrials:NCT00107861]AVONEX® Combination Trial - "ACT" [clinicaltrials:NCT00112034]Efficacy and Safety of BG00012 in MS [clinicaltrials:NCT00168701]Pregnancy Exposure Registry for Avonex (Interferon Beta-1a) [clinicaltrials:NCT00168714]Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma [clinicaltrials:NCT00168727]Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102) [clinicaltrials:NCT00168740]Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS [clinicaltrials:NCT00168766]Safety and Tolerability of Repeat Courses of IM Alefacept [clinicaltrials:NCT00233662]Open-Label Natalizumab Safety Extension Study [clinicaltrials:NCT00276172]A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis [clinicaltrials:NCT00288990]Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis [clinicaltrials:NCT00292422]clinicaltrials:NCT00297232clinicaltrials:NCT00298272clinicaltrials:NCT00306592Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL [clinicaltrials:NCT00319930]clinicaltrials:NCT00344786Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors [clinicaltrials:NCT00345189]A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL) [clinicaltrials:NCT00363636]Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL) [clinicaltrials:NCT00384150]clinicaltrials:NCT00390221Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) [clinicaltrials:NCT00391066]CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study [clinicaltrials:NCT00412412]clinicaltrials:NCT00420212A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS) [clinicaltrials:NCT00424788]Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease [clinicaltrials:NCT00438607]Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease [clinicaltrials:NCT00442780]clinicaltrials:NCT00451451BIIB014 Phase 2a Monotherapy [clinicaltrials:NCT00451815]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis [clinicaltrials:NCT00027300]Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis [clinicaltrials:NCT00030966]Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas [clinicaltrials:NCT00031083]Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL) [clinicaltrials:NCT00046488]Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma [clinicaltrials:NCT00048555]Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma [clinicaltrials:NCT00057343]Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma [clinicaltrials:NCT00090038]Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis [clinicaltrials:NCT00097760]Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) [clinicaltrials:NCT00099489]Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma [clinicaltrials:NCT00102024]Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) [clinicaltrials:NCT00103558]Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors [clinicaltrials:NCT00105170]Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases [clinicaltrials:NCT00107861]AVONEX® Combination Trial - "ACT" [clinicaltrials:NCT00112034]Efficacy and Safety of BG00012 in MS [clinicaltrials:NCT00168701]Pregnancy Exposure Registry for Avonex (Interferon Beta-1a) [clinicaltrials:NCT00168714]Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma [clinicaltrials:NCT00168727]Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102) [clinicaltrials:NCT00168740]Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS [clinicaltrials:NCT00168766]Safety and Tolerability of Repeat Courses of IM Alefacept [clinicaltrials:NCT00233662]Open-Label Natalizumab Safety Extension Study [clinicaltrials:NCT00276172]A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis [clinicaltrials:NCT00288990]Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis [clinicaltrials:NCT00292422]clinicaltrials:NCT00297232clinicaltrials:NCT00298272clinicaltrials:NCT00306592Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL [clinicaltrials:NCT00319930]clinicaltrials:NCT00344786Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors [clinicaltrials:NCT00345189]A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL) [clinicaltrials:NCT00363636]Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL) [clinicaltrials:NCT00384150]clinicaltrials:NCT00390221Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) [clinicaltrials:NCT00391066]CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study [clinicaltrials:NCT00412412]clinicaltrials:NCT00420212A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS) [clinicaltrials:NCT00424788]Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease [clinicaltrials:NCT00438607]Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease [clinicaltrials:NCT00442780]clinicaltrials:NCT00451451BIIB014 Phase 2a Monotherapy [clinicaltrials:NCT00451815]
source [clinicaltrials_vocabulary:source]
Biogen [clinicaltrials_resource:b34193a9204d2f50d15aedf8b222dbad]
Bio2RDF identifier
b34193a9204d2f50d15aedf8b222dbad
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:b34193a9204d2f50d15aedf8b222dbad
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:b34193a9204d2f50d15aedf8b222dbad
title
Biogen
@en
type
label
Biogen [clinicaltrials_resource:b34193a9204d2f50d15aedf8b222dbad]
@en